Treating leukemia: differentiation therapy for mIDH2 AML

Reasons for treating secondary AML as de novo AML.

In a Danish bi-regional registry-based study, we conducted an analysis of the incidence and clinical importance of secondary acute myeloid leukaemia (AML). In a total of 630 cases of AML, we found 157 (25%) cases of secondary AML. The secondary leukaemia arose from MDS (myelodysplastic syndrome) in 77 cases (49%), CMPD (chronic myeloproliferative disorder) in 43 cases (27%) and was therapy-rela...

PRAMEing a picture of differentiation therapy for AML?

Addition of retinoic acid to chemotherapy improves survival of patients with acute myeloid leukemia. This effect is more pronounced in leukemias that express high levels of PRAME. PRAME is an inhibitor of retinoic acid signaling, which may prove to be an important marker for retinoic acid response.

acute myeloid leukemia (aml): the role of maintenance chemo¬therapy

maintenance treatment for patients with acute myeloid leukemia (aml) in remission has recently been controversially discussed and even abandoned by several groups. an analysis of 16 published multicenter trials, however, revealed the highest probabilities of relapse free survival (rfs) in the range of 35-42 % at 4-5 years only in patients assigned to maintenance treatment when adult age and int...

Therapy-related MDS and AML in acute promyelocytic leukemia.

Effective Dendritic Cell-based Immunotherapeutic Vaccines for Acute Myeloid Leukemia (AML)

Acute myeloid leukemia (AML) is a type of poor prognosis hematological malignancies characterized by heterogeneous clonal expansion of myeloid progenitors. Leukemic stem cells are thought to form the majority of a cell population in minimal residual diseases (MRDs) which are resistant to current chemotherapeutic regimens and mediate disease relapse. Current therapeutic vaccine strategies have d...